Global Acute Myeloid Leukaemia market set to grow to $2.8bn by 2022

Wednesday 14 November 2018, Amsterdam

Market Research Report Press Release Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.

The rapid increase in geriatric population is one of the major drivers for the acute myeloid leukaemia market. With age, patients become highly susceptible to diseases due to decreased immunity and degeneration. As per an article published by NCBI, Acute myeloid leukaemia (AML) is the common form of acute leukaemia in adults, accounting for over 80% of all acute leukaemia in those over the age of 18 years.

The lead analyst of the report commented "The growth of the acute myeloid leukaemia market is estimated to be catalysed by opportunities in emerging markets due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness of treatment methods.

There is a need for better therapeutics and treatment options. The increasing incidence and lack of better treatment options pose a lucrative opportunity for the market to grow and expand."


Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals, Teva
Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Publish date : September 2018
Report code : ASDR-468858
Pages : 135

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News